Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for Libervant™ (diazepam) Buccal Film

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement